Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q40446595

about

Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review EGFR Signaling in Liver Diseases Systemic therapy of hepatocellular carcinoma: current status and future perspectives Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells.Molecular genetics of hepatocellular neoplasia.Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial A multidisciplinary approach to the management of hepatocellular carcinoma.Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.Targeting metastatic upper gastrointestinal adenocarcinomas Targeted therapy in hepatocellular carcinoma Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview.3β-hydroxysterol δ24-reductase on the surface of hepatitis C virus-related hepatocellular carcinoma cells can be a target for molecular targeting therapy.Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study.Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.Sorafenib: where do we go from here?Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.Molecular targeted therapies in hepatocellular carcinoma Systemic therapy in hepatocellular carcinoma.Translating the metastasis paradigm from scientific theory to clinical oncology.Evolving therapies in the treatment of hepatocellular carcinoma Molecular therapy for the treatment of hepatocellular carcinoma.Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics eIF5A2 is an alternative pathway for cell proliferation in cetuximab-treated epithelial hepatocellular carcinoma.Let-7a enhances the sensitivity of hepatocellular carcinoma cells to cetuximab by regulating STAT3 expression.The epidermal growth factor receptor: a link between inflammation and liver cancer.Targeted therapy of hepatocellular cancer.TGF-β Mediated Crosstalk Between Malignant Hepatocyte and Tumor Microenvironment in Hepatocellular Carcinoma.Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.Novel inhibitors in development for hepatocellular carcinoma.Systemic therapy for advanced hepatocellular carcinoma: past, present, and future.

P2860

Q21198850-A813956C-3E3A-4CAE-AE13-6BCBD0179D0F Q26771265-4AC63D9D-B6B0-40B9-A201-AFB7FFC6EA25 Q26865844-6CB72ADC-4AF5-48D0-A3CB-71A0C026E9B9 Q30479629-77DDEBCE-D25C-405B-A85E-DA9C3D1DD06A Q33556420-A30FFF78-CFE1-414A-BFF8-B18DA42C7064 Q33660974-1AC8178A-78B2-4E30-92AD-28648CA80E5B Q33680701-B238B572-8FA7-443A-84F0-4CFAAC3D48A8 Q33818746-422A27E5-B996-47CC-837A-F3705F8FAEFC Q33916361-C3910ED3-3488-4D73-A569-57EE6ADFCEF5 Q33990018-F47615F3-3794-453E-A9B6-85FDC253BC59 Q34007879-6796E035-A27F-4680-A175-25100FC89866 Q34253748-690D8505-495A-4A6F-BABE-2E3DD0AB1E80 Q34272887-5F8DD4A1-8255-4E0F-B637-79CF28671C69 Q34409128-A0A67C67-87E7-48F2-938F-2C0F41C3AF58 Q34611637-10B6229A-E283-4830-B0A6-2D7D3ADA7956 Q35000785-CA180C86-8E12-4648-81A9-ED63D3FC5768 Q35207561-E143B4ED-DD7A-431C-B0DC-2F809B466F5A Q35445125-EEF6F83A-C59F-4C67-B90B-585029D80786 Q35501246-4284C230-6778-4798-BC0E-E5FD65479863 Q35541482-E326886B-9BB0-4141-A67B-FB82422D014A Q35602416-9A81E545-A659-4079-A93C-3B17AB904C4D Q35913461-40E4679A-049E-41FC-AC8C-881465166048 Q36335286-F488CF23-6069-47A3-9ACC-9BAD69B6C1C5 Q36378949-72FA4320-F490-4D32-BE10-EC013F21F44D Q36708741-D6ED8F3C-456F-4E2B-948E-6FCF85B35AEB Q36917485-0078C802-D631-46E7-B41F-DB0193F8893A Q37003665-33EDBCF1-4236-4EBC-A5A0-06EF75ABAC9E Q37135733-E40CEAA4-CCFF-498D-BBAB-D0F180E72791 Q37195409-C21B9616-A724-4864-A63C-681D4362A982 Q37290714-9DCC8102-4F2F-436F-932A-E37F6B84CD12 Q37329048-0C8A1649-8E9C-44DA-9D88-4DCEF1791C9E Q37355835-9FD58B7F-B057-4E43-BF3B-A5F671AFCCC3 Q37448092-E5F74C61-098E-42DA-AEF9-89319739F0F7 Q37469797-AE0B16D6-72C1-43DB-93C3-60FD85A5B519 Q37476452-1324C8C7-D5B7-4FDF-A7E9-09F159603A40 Q37674624-4F7F9A25-914D-454A-9C1C-641BCD1D3D9E Q37705967-3CA01FBF-89D6-48F9-B672-5B809D70F31E Q37724256-E7E48828-80AD-4F8B-B3BD-A76686315183 Q37725994-7DA6C714-5EB1-4F92-A316-E2E5B240AE08 Q37734197-0E1A8184-5129-423D-A5EB-A2E12C209500

P2860

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q40446595

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.

@en

type

label

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.

@en

prefLabel

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.

@en

P1433

Q40446595-3A1BBCEC-65F8-4EC1-86DB-A39E89FACAB6

P1476

Q40446595-23653F1A-A310-41FE-A848-ABAA8B20A5A0

P2093

Q40446595-1A9DFE2E-8056-4BD9-9B70-8E4F79557315

Q40446595-24698864-C9F3-454A-ACF0-52E410EB19D6

Q40446595-3693C7D7-CEEE-4AB8-944A-FB372C2AB501

Q40446595-66CBD6B1-2E64-4F34-B750-9461A3328CA9

Q40446595-8A3794BD-EA4D-436B-9FE8-E16835395B76

Q40446595-C3DDD042-941E-44D9-8AB0-248A695588FF

Q40446595-D668C57D-5154-49C0-A8BD-BED5770FDFA7

Q40446595-DA10C5F1-5301-428D-A3B0-450E88673060

Q40446595-DFEC6F43-28BB-4C06-9DEA-2696E94D3204

Q40446595-E41EDF6A-5B89-4722-A555-5FC985E30DAC

P2860

Q40446595-C673E160-1687-49BE-881B-4EFB61D11B88

Q40446595-D7F4B181-EAE4-479C-A6D9-714E8997DDE5

P304

Q40446595-17A6EA62-BB0C-4516-A9D4-B3932CA8E556

P31

Q40446595-206CAEFC-006E-4A88-825F-614B770D020D

P356

Q40446595-15F056B8-5C4C-4A63-BD7C-E3EB3850B6AE

P407

Q40446595-2B02A715-6CF8-403D-A994-26F5CD156678

P433

Q40446595-451BB5D4-21E8-438B-89D5-C091659587B4

P478

Q40446595-B7C8E912-30D2-4399-971D-FE050207DF8F

P50

Q40446595-C56694C2-D9ED-4C25-A8EB-4EEA50E81F49

Q40446595-E8F4C7FE-2F14-4846-BF4D-417223545919

P577

Q40446595-22A27856-7154-400A-9E11-986079552656

P5875

Q40446595-3137A38C-2A78-4AAD-B06D-2EFB1CAC6A02

P698

Q40446595-2847BC1A-7966-4E2D-8CE1-2A189A04AD2D

P921

Q40446595-01E79A3C-28F6-430B-AA9A-E6DB404A015B

P356

P1433

P1476

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.

@en

P2093

Alona Muzikansky

http://www.w3.org/2001/XMLSchema#string

Andrew X Zhu

http://www.w3.org/2001/XMLSchema#string

David P Ryan

http://www.w3.org/2001/XMLSchema#string

Donald P Reitberg

http://www.w3.org/2001/XMLSchema#string

Jeffrey W Clark

http://www.w3.org/2001/XMLSchema#string

Keith Stuart

http://www.w3.org/2001/XMLSchema#string

Kerry Horgan

http://www.w3.org/2001/XMLSchema#string

Lawrence S Blaszkowsky

http://www.w3.org/2001/XMLSchema#string

Pankaj Bhargava

http://www.w3.org/2001/XMLSchema#string

Peter C Enzinger

http://www.w3.org/2001/XMLSchema#string

P2860

Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines

Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma.

P304

581-589

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.22829

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Charles S. Fuchs

Jeffrey A Meyerhardt

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6252896

http://www.w3.org/2001/XMLSchema#string

P698

17583545

http://www.w3.org/2001/XMLSchema#string

P921